Open AccessEffects on hearing and tinnitus following Dupilumab treatment of severe asthma with chronic rhinosinusitis - a case report
Author(s) -
M. Thorsberger,
Celeste Porsbjerg,
J. Yde,
Kasper Aanæs
Publication year - 2021
Publication title -
rhinology online
Language(s) - English
Resource type - Journals
ISSN - 2589-5613
DOI - 10.4193/rhinol/21.002
Subject(s) - dupilumab , tinnitus , medicine , asthma , audiogram , chronic rhinosinusitis , audiology , chronic cough , hearing loss
Background: Dupilumab (anti-IL-4R) is a novel biological agent approved for treatment of severe asthma with chronic rhinosinusitis. Beneficial effects on hearing have only been sparsely decribed. Case presentation: In this case story we present a 48-year woman, who experienced remarkably improved hearing and reduction of tinnitus after initiation of Dupilumab. Progress was monitored by respiratory physicians in collaboration with rhinologists and audiologists. SNOT-22 score improved from 83 to 27 and audiograms obtained before and during treatment illustrate a reduced air-bone gap and an improvement of speech recognition threshold from 25 dB (both ears) to 15 and 10 (left and right ear respectively). Conclusions: This case story implies a beneficial effect of Dupilumab treatment in patients with united airway disease with hearing impairment. The authors suggest an additional otological perspective in addition to standard monitoring.